医学
阿替唑单抗
免疫疗法
佐剂
肿瘤科
内科学
围手术期
肺癌
辅助治疗
疾病
临床试验
彭布罗利珠单抗
癌症
外科
作者
Jordi Remón,Benjamin Besse
标识
DOI:10.1038/s41571-021-00574-1
摘要
Efforts are being made to incorporate immune-checkpoint inhibitors into therapy for early stage non-small-cell lung cancer. The IMpower010 trial of adjuvant atezolizumab has recently become the first study to demonstrate that this strategy can improve disease-free survival in a subset of patients. This trial opens a new area of research in the quest for the optimal perioperative strategy to increase overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI